Zacks Investment Research·Jun 30, 2026
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's WhyPacific Biosciences of California (PACB) closed at $1.68 in the latest trading session, marking a -2.89% move from the prior day.
Pacific Biosciences of California, Inc.(PACB)Earnings, Financials & Key Ratios
PACB•NASDAQ
$1.56
Price updated Jul 7, 2026
AboutPacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.Show more
- Revenue$160M+3.9%
- EBITDA-$53M+87.5%
- Net Income-$546M-76.3%
- EPS (Diluted)-1.82-70.1%
- Gross Margin31.67%+30.8%
- EBITDA Margin-32.91%+88.0%
- Operating Margin-348.46%-13.1%
- Net Margin-341.47%-69.7%
- ROE-213.45%-316.1%
PACB Price & Volume
Pacific Biosciences of California, Inc. (PACB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten Long-Term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and solvency constraints
Key Thesis Takeaways
- Pacific Biosciences faces a precarious outlook as the transition to the Revio platform fails to generate meaningful revenue growth, evidenced by a stagnant 0.1% year-over-year increase in 2026Q1.
- The company's reliance on debt financing has pushed the debt-to-equity ratio to an alarming 297.29, severely eroding the equity base to just $2.4 million.
- Investors should remain cautious as the firm continues to burn cash, with negative free cash flow margins of -128.4% in the most recent quarter, suggesting significant liquidity risks ahead.
Verdict Logic
the company's inability to achieve profitability is underscored by a -102.0% operating margin and a precarious debt-to-equity ratio of 297.29, which suggests a high risk of further dilutive capital raises.
PACB Growth Metrics
Pacific Biosciences of California, Inc. (PACB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.6%
5 Years15.19%
3 Years7.64%
TTM5.04%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM80.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.24%
Return on Capital
10 Years-49.41%
5 Years-29.72%
3 Years-37.5%
Last Year-57.96%
PACB Recent Earnings
Pacific Biosciences of California, Inc. (PACB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.12+29.4%
$0.17
Rev
$37M-6.9%
$40M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.12+36.8%
$0.19
Rev
$45M+3.7%
$43M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.12+25.0%
$0.16
Rev
$38M-13.8%
$45M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.13+27.8%
$0.18
Rev
$40M-0.5%
$40M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.12vs $0.17+29.4% | $37Mvs $40M-6.9% |
| Q1 2026 | Feb 12, 2026 | $0.12vs $0.19+36.8% | $45Mvs $43M+3.7% |
| Q4 2025 | Nov 5, 2025 | $0.12vs $0.16+25.0% | $38Mvs $45M-13.8% |
| Q3 2025 | Aug 7, 2025 | $0.13vs $0.18+27.8% | $40Mvs $40M-0.5% |
Based on last 12 quarters of dataView full earnings history →
Latest PACB News
Recent stock market news and headlines for Pacific Biosciences of California, Inc. (PACB)
Peers Comparison
Key metrics vs top competitors for Pacific Biosciences of California, Inc. (PACB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.56 | $484.54M | -0.86 | 3.89% | -341.47% | -213.45% | — | |
| $191.76 | $29.13B | 35.19 | -0.78% | 19.43% | 32.84% | — | |
| $7.58 | $1.98B | -24.45 | 18.96% | -73.63% | -36.79% | — | |
| $28.31 | $1.46B | -70.78 | 13.79% | -1.98% | -2.61% | — | |
| $516.62 | $191.99B | 29.12 | 3.91% | 15.18% | 13.23% | — | |
| $194.19 | $137.44B | 38.53 | 2.9% | 14.89% | 7.06% | — |
Compare PACB vs Peers
Pacific Biosciences of California, Inc. (PACB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PACB SEC Filings & Documents
Pacific Biosciences of California, Inc. (PACB) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Mar 5, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when PACB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PACB Frequently Asked Questions
Pacific Biosciences of California, Inc. (PACB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Pacific Biosciences of California, Inc.'s revenue?
Pacific Biosciences of California, Inc. (PACB) reported $160.0M in revenue for fiscal year 2025. This represents a 17661% increase from $0.9M in 2008.
How fast is Pacific Biosciences of California, Inc. growing?
Pacific Biosciences of California, Inc. (PACB) grew revenue by 3.9% over the past year. Growth has been modest.
Is PACB profitable?
Pacific Biosciences of California, Inc. (PACB) reported a net loss of $128.6M for fiscal year 2025.
Dividend & Returns
What is PACB's return on equity?
Pacific Biosciences of California, Inc. (PACB) has a return on equity (ROE) of -213.5%. Negative ROE indicates the company is unprofitable.
What is Pacific Biosciences of California, Inc.'s free cash flow?
Pacific Biosciences of California, Inc. (PACB) had negative free cash flow of $116.2M in fiscal year 2025, likely due to heavy capital investments.